Under the terms of the deal, Alnylam will develop an undisclosed investigational, rare genetic disease asset through the completion of investigational new disease (IND)-enabling studies.
Sanofi will be responsible for the product’s further development and commercialisation. If the candidate is approved, Alnylam will be eligible for tiered double-digit royalties on its net sales worldwide.
Furthermore, the partners have agreed to change select terms of their equity agreement to provide Sanofi with access to its lock-up of Alnylam stock holdings.
Sanofi Research and Development global head John Reed said: “Our alliance with Alnylam has successfully brought one important medicine to patients with ATTR amyloidosis and it also has spawned a molecule that is in pivotal clinical trials for people with haemophilia.
“As we wrap up this phase of our programme with Alnylam, we remain committed to advancing therapies for patients with rare diseases and rare blood disorders.”
In January last year, Sanofi and Alnylam restructured their alliance, with Sanofi receiving global development and commercialisation rights to fitusiran, an investigational RNAi therapeutic for haemophilia A and B treatment.
Meanwhile, Alnylam gained global development and commercialisation rights to patisiran and ALN-TTRsc02 (vutrisiran) in ATTR amyloidosis.
Following the closing of the option phase, these material collaboration terms for patisiran, vutrisiran and fitusiran will remain unchanged.